---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-001971"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:40:55.131906+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics receives Nasdaq delisting notice; trading to move to OTC Pink effective Jan 14

## Summary
- Nasdaq Staff determined to delist CODX due to continued non-compliance with minimum bid price rule.
- Trading on Nasdaq suspended from open on Jan 14, 2026; shares expected to trade on OTC Pink under CODX.
- Company plans to request a hearing with Nasdaq Hearings Panel to address bid price deficiency.
- Since Jan 2, 2026 (1-for-30 reverse split effective), bid price closed at or above $1.00; may seek compliance if 10 consecutive days ending Jan 15 show $1.00.
- Prior non-compliance notice Jan 10, 2025; two compliance periods expired Jan 5, 2026 without meeting rule.

## SEC filing metadata
- accession: 0001493152-26-001971
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-001971
- JSON: https://secwatch.observer/filing/0001493152-26-001971.json
- Plain text: https://secwatch.observer/filing/0001493152-26-001971.txt

## Source-grounded claims
- claim_id: 261b568cd7b2030ed2d81edf468a4a8fc6e8b314
  claim: Co-Diagnostics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(a)(1)(B)(ii)(d)).
  evidence_excerpt: January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.